Search the Newsreel

Mineralys Therapeutics earnings up next as losses expected to widen

Mineralys Therapeutics is preparing to announce its second-quarter earnings, with analysts anticipating a widening of losses as the company advances its hypertension drug, lorundrostat, towards a potential FDA decision in December 2026. Despite the projected increase in losses, reflecting ongoing cash burn for commercialization, …

Kalyani Steels Standalone June 2026 Net Sales at Rs 464.58 crore, up 4.93% Y-o-Y

Annaly Capital Management Inc $NLY Shares Bought by Bank of America Corp DE

Kalyan Jewellers India Shares Fall 2.19%, Company Declares Final Dividend of Rs 2.50 Per Share

Kalyani Forge makes Q1 FY27 investor meet recordings available online

Health Catalyst, Inc. (NASDAQ:HCAT) Receives Consensus Rating of "Hold" from Analysts

Health Catalyst, Inc. (NASDAQ:HCAT) has received a consensus "Hold" rating from thirteen analysts, with an average 12-month price target of $2.95. The company recently reported better-than-expected quarterly EPS of $0.04 and revenue of $70.49 million, though it remains unprofitable with a negative net margin. …

Kalyani Forge Q1 FY27: ROCE hits 22%, PAT surges 218% on margin expansion

Mineralys Therapeutics, Inc. Q2 2026 Earnings Call Summary

Daily Brief India: Mrs Bectors Food Specialities, Kalyani Investment, Shiprocket, Knowledge Realty Trust, Encube Ethicals Limited, National Stock Exchange and more

Mineralys Therapeutics falls 8% on second quarter EPS miss

Mineralys Therapeutics (NASDAQ:MLYS) reported a wider-than-expected second-quarter loss of $2.85 per share, missing analyst estimates of $2.63 per share. This loss was primarily due to a $200 million upfront payment to Tanabe and increased research and development, along with general and administrative expenses. Despite …

Mineralys Therapeutics (NASDAQ: MLYS) widens loss but builds $661M cash war chest

Mineralys Therapeutics reported a widened net loss of $280.4 million for the first half of 2026, primarily due to a $200 million upfront R&D charge for a perpetual, royalty-free license for its hypertension candidate, lorundrostat. Despite the loss, the company strengthened its financial position …

Press Release: Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Mineralys Therapeutics announced its second quarter 2026 financial results, highlighting progress in its clinical programs. The company provided an update on its corporate activities, focusing on key developments and future outlook. This release details the financial performance and strategic advancements made during the quarter.

Wrapped Verisk Analytics Tokenized Stock (xStock) price today, wVRSKx to USD live price, marketcap and chart

This CoinMarketCap page provides live price, market cap, and chart information for Wrapped Verisk Analytics Tokenized Stock (xStock), identified by the symbol wVRSKx. It indicates that the token currently has a total supply and circulating supply of 0, with a maximum supply not provided. …

Mineralys Therapeutics (NASDAQ:MLYS) Announces Earnings Results

Mineralys' Blood-Pressure Candidate Has Dec. 22 FDA Target Date

Mineralys Therapeutics reported its Q2 2026 financial results, including a $241 million net loss, and provided a corporate update on its aldosterone synthase inhibitor, lorundrostat. The FDA has set a PDUFA target date of December 22, 2026, for lorundrostat, and Mineralys is actively preparing …

How Mineralys Therapeutics Inc. (MLYS) Affects Rotational Strategy Timing

Mineralys Therapeutics Inc. (MLYS) shows a positive near-term sentiment with a potential shift, indicating broader weak alignment within a mid-channel oscillation pattern. AI models suggest specific trading strategies for different risk profiles, highlighting a notable 109.0:1 risk-reward setup targeting a 29.4% gain versus 0.3% …

Mineralys Therapeutics, Inc. Q2 2026: Net loss $(241.1)M, EPS $(2.85) — 10-Q Summary

Mineralys Therapeutics, Inc. reported a significant increase in its net loss for Q2 2026, reaching $(241.1)M, or $(2.85) per diluted share, compared to $(43.3)M in Q2 2025, with no product revenue generated to date. The company highlighted progress in its pipeline, including the NDA …

MINERALYS THERAPEUTICS ($MLYS) Releases Q2 2026 Earnings

MINERALYS THERAPEUTICS ($MLYS) reported its Q2 2026 earnings, missing analyst estimates with -$2.85 per share against an expected -$0.55, and revenue matching expectations at $0. Following the announcement, the stock price declined by 4.32%. The article also details significant insider trading activity, with 39 …

Health Catalyst (NASDAQ:HCAT) Price Target Cut to $2.00 by Analysts at Citigroup

Citigroup has reduced its price target for Health Catalyst (NASDAQ:HCAT) from $2.50 to $2.00, while maintaining a "neutral" rating, indicating a potential 12% upside from its previous close. Despite beating quarterly EPS and revenue estimates, the company continues to report substantial losses, and analysts …

HCAT Maintained by Citigroup -- Price Target Lowered to $2.00

Citigroup has maintained a neutral rating for Health Catalyst (HCAT) but lowered its price target from $2.50 to $2.00. Despite the stock being potentially undervalued by 58.8% according to GuruFocus's GF Value, concerns remain about the company's profitability and valuation. Investors are advised to …

Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Mineralys Therapeutics announced its financial results for the second quarter ended June 30, 2026, and provided a corporate update. The company is preparing for the commercial launch of lorundrostat, pending FDA approval by the PDUFA target date of December 22, 2026, and has appointed …

Annaly’s Shift Toward Higher Coupon MBS Might Change The Case For Investing In Annaly (NLY)

Annaly Capital Management is focusing on higher coupon Agency mortgage-backed securities (6%-6.5%) to enhance economic returns and margins, alongside a perception of its shares being undervalued. This strategy, combined with strong Q2 2026 results, aims to improve earnings despite inherent interest rate and funding …

Why Karnalyte Resources Inc. stock is sliding today

Qualys (QLYS) Is Up 20.0% After Raising 2026 Outlook And Expanding AI Security Suite

Qualys (QLYS) saw its stock rise 20.0% after reporting strong Q2 2026 results with increased sales and net income, and subsequently raising its full-year revenue and earnings guidance. The company also expanded its AI-driven cybersecurity offerings with InstaScan and TotalAI, joining the CSAI Foundation …

Verisk Stock (NASDAQ:VRSK) Loses $1.39 Billion as Court Revives AccuLynx Deal

Verisk (NASDAQ:VRSK) shares dropped 5.55%, erasing $1.39 billion in market value, after a Delaware court revived its obligations to acquire AccuLynx for $2.35 billion. The ruling requires Verisk to seek antitrust clearance and covers AccuLynx's direct costs, but does not immediately close the deal. …

Verisk Analytics, Inc. $VRSK Shares Purchased by Assenagon Asset Management S.A.

Health Catalyst Inc (HCAT) Earnings Forecast: Future EPS & Revenue Growth Estimates

Stock Picks Today: Bharat Forge, Gland Pharma, Info Edge, Fractal Analytics, Vodafone And More On Brokerages' Radar

Mineralys Therapeutics (MLYS) – David Rodman files Rule 144 for stock sale

David Rodman has filed a Rule 144 notice to sell 2,170 shares of Mineralys Therapeutics, Inc. common stock through Merrill Lynch on August 10, 2026. This planned sale is connected to the exercise of employee stock options via a cashless exercise. The filing also …

Verisk Analytics Inc. stock underperforms Monday when compared to competitors

Verisk Analytics Inc. (VRSK) shares dropped 5.55% on Monday, closing at $181.18, despite a broader market decline with the S&P 500 Index and Dow Jones Industrial Average also falling. This performance marked the end of a two-day winning streak for the company's stock.

We Think You Can Look Beyond Verisk Analytics' (NASDAQ:VRSK) Lackluster Earnings

This article suggests that investors should not be overly concerned by Verisk Analytics' recent disappointing earnings, as the company is expected to see a significant rebound in earnings per share (EPS) over the next couple of years. Despite falling short of analyst estimates in …

Why is Verisk Analytics stock sliding today?

Verisk Analytics (VRSK) stock fell 5.6% after a Delaware Chancery Court ruling compelled the company to proceed with its $2.35 billion acquisition of AccuLynx, a deal Verisk had attempted to terminate in December 2025. The court also awarded damages to AccuLynx, and the transaction …

Verisk Analytics (NASDAQ:VRSK) Shares Gap Down - Here's Why

Verisk Analytics (NASDAQ:VRSK) shares gapped down by about 5% on Monday, opening at $180.90 after closing at $191.82, despite exceeding quarterly earnings expectations with $1.98 EPS and $806.3 million in revenue. The company also declared a quarterly dividend of $0.50 per share, while insiders …

REG - Renalytix PLC - Holding(s) in Company

Verisk 'strongly Disagrees' With Delaware Court Ruling On AccuLynx

(RTTNews) - Verisk Analytics, Inc. (VRSK) said on Monday it "strongly disagrees" with a Delaware Chancery Court ruling regarding AccuLynx, and is evaluating options including a possible appeal. "We appreciate the expedited response from the court but strongly disagree with the decision," the data …

Court rejects Verisk plan to cancel $2.35 billion merger

A Delaware Chancery Court has rejected Verisk's attempt to terminate its $2.35 billion merger with AccuLynx, ordering Verisk to proceed with "commercially reasonable efforts" to obtain regulatory approval. The ruling stemmed from Verisk's handling of an FTC antitrust review, which Verisk initiated by attempting …